Recombinant adjuvanted respiratory syncytial virus vaccine - MAXVAX Biotechnology
Latest Information Update: 16 Dec 2025
At a glance
- Originator MAXVAX Biotechnology
- Class Protein vaccines; Respiratory syncytial virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Respiratory syncytial virus infections
Most Recent Events
- 22 Oct 2025 Phase-III clinical trials in Respiratory syncytial virus infections (Prevention, In the elderly) in China (IM) (NCT07272434)
- 13 Nov 2024 Phase-I clinical trials in Respiratory syncytial virus infections (Prevention) in China (IM) (NCT06642558)
- 16 Oct 2024 MAXVAX Biotechnology plans a phase I/II trial for Respiratory syncytial virus infections (Prevention) in China (IM) in October 2024 (NCT06642558)